EDITORIAL

1654 Teneligliptin: A potential therapeutic approach for diabetic cardiomyopathy
   Al Madhoun A

1659 Diabetic cardiomyopathy: Importance of direct evidence to support the roles of NOD-like receptor protein 3 inflammasome and pyroptosis
   Cai L, Tan Y, Islam MS, Horowitz M, Wintergerst KA

1663 Diabetes and susceptibility to COVID-19: Risk factors and preventive and therapeutic strategies

1672 Periodontal disease: A silent factor in the development and progression of diabetic retinopathy
   Lomelí Martínez SM, Cortés Trujillo I, Martínez Nieto M, Mercado González AE

1677 Diabetic cardiomyopathy: Emerging therapeutic options
   Fernandez CJ, Shetty S, Pappachan JM

1683 Urgent call for attention to diabetes-associated hospital infections
   Yu XL, Zhou LY, Huang X, Li XY, Pan QQ, Wang MK, Yang JS

REVIEW

1692 Bariatric surgery and diabetes: Current challenges and perspectives
   He YF, Hu XD, Liu JQ, Li HM, Lu SF

MINIREVIEWS

1704 Mechanism underlying the effects of exercise against type 2 diabetes: A review on research progress
   Peng CJ, Chen S, Yan SY, Zhao JN, Luo ZW, Qian Y, Zhao GL

1712 Advances in the treatment of diabetic peripheral neuropathy by modulating gut microbiota with traditional Chinese medicine
   Li YY, Guan RQ, Hong ZB, Wang YL, Pan LM

ORIGINAL ARTICLE

Case Control Study

1717 Autoantibodies against beta cells to predict early insulin requirements in pediatric patients with clinically diagnosed type 2 diabetes
   Molina JM, Medina PG, Gomez RA, Herrera JR, Martínez NL, Hernández B, García Y
Contents

Retrospective Study

1726  Clinically significant changes in anal sphincter hiatal area in patients with gestational diabetes mellitus and pelvic organ prolapse

Wang QH, Liu LH, Ying H, Chen MX, Zhou CJ, Li H

Randomized Controlled Trial

1734  Efficacy comparison of multipoint and single point scanning panretinal laser photocoagulation in non-proliferative diabetic retinopathy treatment

Zhang YZ, Gong H, Yang J, Bu JP, Yang HL

Clinical and Translational Research

1742  Association between composite dietary antioxidant index and stroke among individuals with diabetes


Basic Study

1753  Functional analysis of the novel mitochondrial tRNA\textsuperscript{Trp} and tRNA\textsuperscript{Ser(AGY)} variants associated with type 2 diabetes mellitus

Ding Y, Yu XJ, Guo QX, Leng JH

1764  Intestinal glucagon-like peptide-1: A new player associated with impaired counterregulatory responses to hypoglycaemia in type 1 diabetic mice

Jin FX, Wang Y, Li MN, Li RJ, Guo JT

1778  Mitigating diabetes-related complications: Empowering metformin with cholecalciferol and taurine supplementation in type 2 diabetic rats

Attia MS, Ayman F, Attia MS, Yahya G, Zahra MH, Khalil MMI, Diab AAA

SYSTEMATIC REVIEWS

1793  Safety of teplizumab in patients with high-risk for diabetes mellitus type 1: A systematic review


META-ANALYSIS

1802  Circulating glycated albumin levels and gestational diabetes mellitus

Xiong W, Zeng ZH, Xu Y, Li H, Lin H

CASE REPORT

1811  Transient diabetes mellitus with ABCC8 variant successfully treated with sulfonylurea: Two case reports and review of literature

Shen LH, Cui Y, Fu DX, Yang W, Wu SN, Wang HZ, Yang HH, Chen YX, Wei HY
LETTER TO THE EDITOR

1820  Enhancing diabetic retinopathy screening: Non-mydriatic fundus photography-assisted telemedicine for improved clinical management

   Szulborski KJ, Ramsey DJ

1824  Vitamin D and selenium for type 2 diabetes mellitus with Hashimoto’s thyroiditis: Dosage and duration insights

   Yu YF, Shangguan XL, Tan DN, Qin LN, Yu R
ABOUT COVER

Peer Review of World Journal of Diabetes, Mustafa Arslan, MD, Professor, Department of Anesthesiology and Reanimation, School of Medicine, Yenimahalle 48, Sok Seda Apt 24-17, Ankara 06500, Türkiye. mustarslan@gmail.com

AIMS AND SCOPE

The primary aim of World Journal of Diabetes (WJD, World J Diabetes) is to provide scholars and readers from various fields of diabetes with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJD mainly publishes articles reporting research results and findings obtained in the field of diabetes and covering a wide range of topics including risk factors for diabetes, diabetes complications, experimental diabetes mellitus, type 1 diabetes mellitus, type 2 diabetes mellitus, gestational diabetes, diabetic angiopathies, diabetic cardiomyopathies, diabetic coma, diabetic ketoacidosis, diabetic nephropathies, diabetic neuropathies, Donohue syndrome, fetal macrosomia, and prediabetic state.

INDEXING/ABSTRACTING

The WJD is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Current Contents/Clinical Medicine, Journal Citation Reports/Science Edition, PubMed, PubMed Central, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2024 Edition of Journal Citation Reports® cites the 2023 journal impact factor (JIF) for WJD as 4.2; JIF without journal self cites: 4.1; 5-year JIF: 4.2; JIF Rank: 40/186 in endocrinology and metabolism; JIF Quartile: Q1; and 5-year JIF Quartile: Q2.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Yu-Xi Chen; Production Department Director: Xu Gu; Cover Editor: Jia-Ru Fan.

NAME OF JOURNAL
World Journal of Diabetes

ISSN
ISSN 1948-9358 (online)

LAUNCH DATE
June 15, 2010

FREQUENCY
Monthly

EDITORS-IN-CHIEF
Lu Cai, Md. Shahidul Islam, Michael Horowitz

EDITORIAL BOARD MEMBERS

PUBLICATION DATE
August 15, 2024

COPYRIGHT
© 2024 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS
https://www.wjgnet.com/bpg/gerinfo/204

GUIDELINES FOR ETHICS DOCUMENTS
https://www.wjgnet.com/bpg/gerinfo/287

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
https://www.wjgnet.com/bpg/gerinfo/240

PUBLICATION ETHICS
https://www.wjgnet.com/bpg/gerinfo/288

PUBLICATION MISCONDUCT
https://www.wjgnet.com/bpg/gerinfo/208

ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/bpg/gerinfo/242

STEPS FOR SUBMITTING MANUSCRIPTS
https://www.wjgnet.com/bpg/gerinfo/239

ONLINE SUBMISSION
https://www.f6publishing.com

© 2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
E-mail: office@baishideng.com https://www.wjgnet.com
Advances in the treatment of diabetic peripheral neuropathy by modulating gut microbiota with traditional Chinese medicine

Ye-Yao Li, Rui-Qian Guan, Zhi-Bo Hong, Yao-Lei Wang, Li-Min Pan

Abstract

Diabetic peripheral neuropathy (DPN) is one of the strongest risk factors for diabetic foot ulcers (neuropathic ulcerations) and the existing ulcers may further deteriorate due to the damage to sensory neurons. Moreover, the resulting numbness in the limbs causes difficulty in discovering these ulcerations in a short time. DPN is associated with gut microbiota dysbiosis. Traditional Chinese medicine (TCM) compounds such as Shenqi Dihuang Decoction, Huangkui Capsules and Qidi Tangshen Granules can reduce the clinical symptoms of diabetic nephropathy by modulating gut microbiota. The current review discusses whether TCM compounds can reduce the risk of DPN by improving gut microbiota.

Key Words: Diabetes; Peripheral neuropathy; Traditional Chinese medicine; Gut microbiota; Diabetic foot ulcer; Treatment

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
INTRODUCTION

Diabetic peripheral neuropathy (DPN) is one of the commonest complications in patients with diabetes and the prevalence of DPN is as high as 50% and maybe even higher, which is also one of the main contributors of the high mortality in patients with diabetes. The duration of DPN is long with poor outcomes[1,2]. DPN is a heterogeneous disease and it has different symptoms which primarily includes neurological disorders such as limb numbness, usually symmetrical, stabbing pain and muscle weakness. Inappropriate treatment of DPN may lead to ulcers and gangrene, which probably results in limb loss and seriously affects quality of life in this population[3,4].

DPN is common in both type 1 and type 2 diabetes. The majority of preclinical and clinical studies focus on the pathogenic cause of hyperglycemia because pretty good control of blood glucose can delay the progression of DPN. Studies using diabetic animal models have confirmed several potential mechanisms to produce glucotoxicity and damage to the nervous system including post-translational modifications of proteins with glycans, aldose reductase, glycolysis and increased glucose metabolism through other pathways for the catabolism of glucose. However, it is becoming increasingly evident that factors except for hyperglycemia may also cause the occurrence, development and severity of neuropathy and neuropathic pain[5,6]. For example, peripheral nerves contain insulin receptors that transduce the neurotrophic and neurosupportive properties of insulin, independent of systemic glucose regulation, while it has become a focus of concern that the detection of neuropathy and neuropathic pain in patients with metabolic syndrome and poor glycemic control to protect against the pathogenic role of dyslipidemia in patients with type 2 diabetes and neuropathy[7-9].

DPN usually affects the sensory neuropathy and sensorimotor neuropathy. The sensory neuropathy is the most common form of DPN in patients with diabetes in clinical practice. It is characterized by gradual loss of nerve fibers of different sizes. In this progressive disease, the distal portions of the nerves in hands and feet are first affected with retraction of sensory axons at the end of the peripheral nervous system. This phenomenon is usually called “stocking & glove neuropathy”, which reflects damage to the longest sensory axons and thus is considered as a length-dependent neuropathy[10,11]. The reduction in the sensation and feeling is one of the commonest and earliest patterns of DPN and these symptoms occur gradually including tingling on the toes, pain and loss of feeling.

Clinical evidence for motor dysfunction is a little unusual in patients with diabetes and the symptoms only appear in 1% to 6% patients, usually in those confirmed with DPN. In the animal models of diabetes, early decreased motor nerve conduction velocities can be easily discovered. However, in both animal models and human studies, it has been proved that compound muscle action potential amplitude and muscular strength are reduced[12-15]. Although hyperglycemia is one of the factors that induce the development of nerve injurie, recently, evidence has demonstrated that damage to the small fibers of the peripheral nervous system may occur in individuals with impaired glucose tolerance independent of the diagnosis of hyperglycemia and diabetes[16]. In addition, keeping blood glucose under control can partly prevent and/or postpone the occurrence of DPN in patients with type 1 diabetes. However, it hardly benefits patients with type 2 diabetes. Hence, other diseases besides hyperglycemia may have an influence on the occurrence and development of DPN in type 2 diabetes. The multitude clinical manifestations of DPN including pain in 15% to 30% patients makes the identification of pathophysiology and treatment of DPN challenging[17-20].

ASSOCIATION BETWEEN GUT MICROBIOTA AND DPN

Risk factors for DPN include duration of diabetes, age, hemoglobin A1c (HbA1c), diabetic retinopathy, smoking and body mass index. A successful way of managing DPN involves exercise in combination with altered lifestyle and targeted diets as well as medication intervention. Studies showed that the occurrence of diabetes and its complications are associated with dysbiosis of the gut microbiota. The development of these disease are mainly related to the increased intestinal permeability, for which bacterial by-products can enhance inflammation by permeating the leaky intestinal barrier[21-23]. Species such as Lactobacillus fermentans, Akkermania muciniphila, Bacteroides fragilis, and Enterococcus rosenbergii have been discovered to be associated with insulin sensitivity and glucose metabolism[24-26]. Gut bacteria Akkermania may impact the effects of metformin on glucose metabolism. Bifidobacterium and Lactobacillus spp. play a predominant role in the repair of the intestinal mucosal barrier. Bifidobacterium spp. that is discovered to be capable of producing bacteriocins is negatively associated with inflammation, hyperglycemia, and insulin resistance through preventing mucosal adhesion and maintaining intestinal barrier function. Probiotics and yogurt containing Bifidobacterium and Lactobacillus can reduce fasting blood glucose and HbA1c in patients with diabetes. Based on this, we can come to a conclusion that Bifidobacterium and Lactobacillus can inhibit the potential intestinal pathogens and enhance intestinal antioxidiant capacity and digestive enzyme activities. Fecal microbials, kinds of Gram-negative bacteria, are negatively associated with HbA1c and can increase intestinal synthesis of glucagon like peptide-1, peptide YY, acetate and butyrate, and maintain blood glucose homeostasis[27].
MODULATING GUT MICROBIOTA WITH TRADITIONAL CHINESE MEDICINE FOR DPN

According to traditional Chinese medicine (TCM), DPN belongs to the field of “Xiaoke Disease”. It is induced by the protracted course of not cured diabetes, poor glycemic control and erosion of the nerve cells. It is generally agreed that “internal heat” oriented pathogenesis of “deficiency of Yin and Jin and excess of dryness and heat” induced by congenital deficiency, long established inappropriate diet, long period of emotional disorder and overstrain associated disorder of internal organs are probably cause of diabetes. Lung, spleen and especially kidney are most affected locations. Gut microbiota dysbiosis will result in intestinal microbial imbalance and insulin resistance, which in further weaken one’s physical defenses against infection providing a chance for the six evils to attack the human body. TCM have the potential to lessen the symptoms of DPN by modulating gut microbiota which is out of balance. TCM compounds follow the compatibility principle of “monarch, minister, assistant, and guide”, which means herbs interact and restrict each other to achieve the optimally holistic effect through multiple targets, levels multiple pathways. For example, Shenqi Dihuang Decoction can regulate the spleen and stomach consequently building a healthy gut microbiome and constructing an integrated intestinal mucosal barrier[28].

Moreover, Huangkui Capsule’s pharmacological effects, such as anti-inflammatory, antiviral, antibacterial, etc. can modulate the balance of gut microbiota from the perspective of inflammation treatment. Studies showed that adding Huangkui Capsule to the experimental group achieved decrease in 24 hours urine albumin-creatinine ratio and blood urea nitrogen content and increase in the number of Gram positive and negative bacteria in the intestine compared with the control group, indicating Huangkui Capsule can relieve the clinical symptoms of diabetic nephropathy[29]. Other studies demonstrated that Qidi Tangshen Granules can improve gut microbiota composition, reduce serum total bile acid level to alleviate the clinical symptoms of diabetic nephropathy[30]. In addition, TCM compounds such as Gegen Qinlian Decoction, Bupi Yishen formular, Baoshen formular, Qinshi Shenshu Capsules, Sanhuang Yishen Capsules and Fuzi L芝hong Pills also can improve the microorganism environment of intestines and stomach by modulating gut microbiota, suppressing the proliferation of harmful bacteria and increasing good bacteria in the gut. Studies[31,32] found those TCMs with effectiveness characterized by tonifying spleen, lifting Yang and Qi and harmonizing the stomach and intestines, and dredging Fu organs and sinking turbidity can actively alleviate nerve pain, repair damaged nerves and regulate the generation of inflammatory mediators through modulating gut microbiota. Meanwhile, the gut microbiota and its metabolic products can regulate glucose metabolism slowly, mediate immune response, regulate and promote the release of various signaling factors and facilitate recovery from DPN.

Diabetes is a multi-factor caused disease and its onset and development are thought to be profoundly influenced by the environment and hereditary factors. It is the main cause of Renal failure, cardiovascular disease, and retinopathy. A great microbial ecosystem lives in the human digestive tract and it co-evolutes with human beings to realize mutual benefits, maintain human health and prevent diseases. According to the “gut-kidney axis” hypothesis, gut microbiota dysbiosis is associated with diabetes and there is a mutual causality relationship between them. Gut microbiota can activate immune cells with its metabolic products and other constituents to trigger inflammatory reaction and accelerate the progression of complications in diabetes. Gut microbiota community derived antigens can induce conventional T cells differentiate into multiple effector cells such as Th2 cells, Th17 cells and T cells (Tregs) to regulate autoimmune response and immune homeostasis and have an impact on the onset and development of DPN. More and more evidence showed that changes in gut microbiota composition and function are associated with the increased risks for the onset and development of diabetes and its complications. Some studies investigating the influence of probiotic administration on blood glucose control and renal function in patients with diabetic nephropathy found that the use of probiotics (Bifidobacterium, Lactobacillus acidophilus, and Streptococcus thermophilus) can modulate gut microbiota in these patients, improve blood glucose control, and reduce fasting blood glucose. 2 hours postprandial serum glucose, HbA1c and microalbuminuria/creatinine (mAlb/Cr) levels with boosting therapeutic potential in the clinical practice[33-35]. The mechanism of its blood glucose lowering is probiotics can promote gut microbiota to yield insulinotropic polypeptide and glucagon-like peptide-1, which stimulate muscle glucose uptake and by this way reduce blood glucose.

Microbiome symbiosis plays a crucial role in regulating metabolism and reducing the risks for diabetes. However, the underlying mechanism has not been well understood[36,37] (Table 1). According to TCM, imbalance of spleen Qi’s lifting and sinking function will further affect the intestine’s digestion, absorption and elimination work. When Zhuo-Du (turbid-toxin) accumulates in the intestines, it is apt to cause gut microbiota dysbiosis with reduced number of beneficial microbe and overrun of harmful microbe. Gut microbiota dysbiosis and the imbalance of microecology will affect liver, spleen and kidney[38-40]. Studies showed that Huangkui Capsules can regulate the blood glucose level, elevate the distribution and subsets of gut microbiota and improve kidney function in patients with diabetic nephropathy[24].

CONCLUSION

Above all, DPN is associated with gut microbiota dysbiosis in diabetes. TCM compounds with the effectiveness of gut microbiota dysbiosis modulation such as Shenqi Dihuang Decoction, Huangkui Capsules and Qidi Tangshen Granules can reduce the relevant clinical symptoms of DPN. With diagnosis and treatment on the basis of an overall analysis of the illness and the patient’s condition, TCM can modulate the species and amounts of gut microbiota to realize the balance and diversity of gut microbiota. In the further, TCM’s role in modulating gut microbiota will gain increasing attention in the clinical practice. Relevant researches are warrant to profoundly investigate various TCMs’ therapeutic efficacy for the complications of diabetes.
Role of microbiome symbiosis in regulating metabolism and reducing the risks for diabetes

Table 1 Microbiome symbiosis plays a crucial role in regulating metabolism and reducing the risks for diabetes

<table>
<thead>
<tr>
<th>Item</th>
<th>Role of microbiome symbiosis in regulating metabolism and reducing the risks for diabetes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Gut microbiota dysbiosis results in the production of short chain fatty acids such as butyric acid, propionic acid, and acetic acid, which will ruin the intestinal barrier integrity, activate inflammatory signaling cascade response and cause damage to multiple organs</td>
</tr>
<tr>
<td>2</td>
<td>Trimethylamine nitrogen oxide produced by the gut microbiota will increase the accumulation of cholesterol, which will lead to insulin resistance and raise the risk for diabetes</td>
</tr>
<tr>
<td>3</td>
<td>It is demonstrated that changes in the gut microbiota groups have an effect on intestinal permeability and inflammation in diabetes</td>
</tr>
</tbody>
</table>

Table 1: Microbiome symbiosis plays a crucial role in regulating metabolism and reducing the risks for diabetes

**References**


